

VIGIL - Use of PCR-SARS-CoV-2 in Children (VIGIL)

Head :JUNG Camille

Last update : 05/05/2021 | Version : 1 | ID : 73890

General	
Identification	
Detailed name	Use of PCR-SARS-CoV-2 in Children (VIGIL)
Sign or acronym	VIGIL
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation	NCT04412317
General Aspects	
Medical area	Infectious diseases
Study in connection with Covid-19	Yes
Scientific investigator(s) (Contact)	
Name of the director	JUNG
Surname	Camille
Email	camille.jung@chicreteil.fr
Collaborations	
Participation in projects, networks and consortia	Yes
Funding	
Governance of the database	
Sponsor(s) or organisation(s) responsible	Créteil Intermunicipal Hospital
Organisation status	Public
Presence of scientific or steering committees	Yes

Additional contact	
Name of the contact	LEVY
Surname	Corinne
Email	corinne.levy@activ-france.fr
Organization	ACTIV
Main features	
Type of database	
Type of database	Study databases
Study databases (details)	Cohort study
Database recruitment is carried out by an intermediary	A selection of health care professionals
Database recruitment is carried out as part of an interventional study	No
Database objective	
Main objective	Percentage of patients positive for Covid-19
Inclusion criteria	Children <15 years indication for PCR or rapid antigen test for Covid-19
Population type	
Age	Newborns (birth to 28 days) Infant (28 days to 2 years) Early childhood (2 to 5 years) Childhood (6 to 13 years) Adolescence (13 to 18 years)
Population covered	General population
Pathology	
Gender	Male Woman
Geography area	National
Data collection	
Dates	

Size of the database	
Size of the database (number of individuals)	[500-1000[individuals
Data	
Database activity	Current data collection
Type of data collected	Clinical data Paraclinical data
Presence of a biobank	No
Procedures	
Followed pathology	
Promotion and access	
Promotion	
Access	